Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 4/20 | 0.81 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.81 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.57 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.55 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.55 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.55 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.50 |
| ▸ | SRC | P12931 | 1/20 | 0.49 |
| ▸ | TDP2 | O95551 | 1/20 | 0.48 |
| ▸ | CASP3 | P42574 | 1/20 | 0.48 |
| ▸ | CASP7 | P55210 | 1/20 | 0.48 |
| ▸ | CASP9 | P55211 | 1/20 | 0.48 |
| ▸ | CASP6 | P55212 | 1/20 | 0.48 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxindole SCHEMBL3866757 | 0.93 | AHR (0.75) | AHRPDK2PDE3BPDE3ANPC1 | |
| Oxindole SCHEMBL19504 | 0.90 | AHR (1.00) | AHRPDK2PDE3BPDE3ANPC1 | |
| Oxindole SCHEMBL29358826 | 0.90 | AHR (1.00) | AHRPDK2PDE3BPDE3ANPC1 | |
| Oxindole SCHEMBL1144643 | 0.90 | AHR (1.00) | AHRPDK2PDE3BPDE3ANPC1 | |
| Oxindole SCHEMBL14324689 | 0.89 | AHR (0.75) | AHRPDK2PDE3BPDE3ANPC1 | |
| Oxindole SCHEMBL5624006 | 0.88 | AHR (0.95) | AHRPDK2PDE3BPDE3ANPC1 | |
| Oxindole SCHEMBL4720301 | 0.88 | AHR (0.95) | AHRPDK2PDE3BPDE3ANPC1 | |
| Oxindole SCHEMBL1236964 | 0.88 | AHR (0.95) | AHRPDK2PDE3BPDE3ANPC1 | |
| Oxindole SCHEMBL15636313 | 0.88 | AHR (0.95) | AHRPDK2PDE3BPDE3ANPC1 | |
| Oxindole SCHEMBL5502064 | 0.88 | AHR (0.95) | AHRPDK2PDE3BPDE3ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7655662-B2 | (Indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)-pyrazines for treating glaucoma and controlling intraocular pressure | ALCON RESEARCH, LTD. (US) | 2010-02-02 | — | — | US | disclosed |
| US-7655662-B2 | (Indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)-pyrazines for treating glaucoma and controlling intraocular pressure | ALCON RESEARCH, LTD. (US) | 2010-02-02 | — | — | US | disclosed |
| US-7655662-B2 | (Indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)-pyrazines for treating glaucoma and controlling intraocular pressure | ALCON RESEARCH, LTD. (US) | 2010-02-02 | — | — | US | disclosed |
| CN-101340912-A | (indazol-5-yl) -pyrazines and (1, 3-dihydro-indol-2-one) -pyrazines for the treatment of RHO kinase mediated diseases and conditions | ALCON MFG LTD (US) | 2009-01-07 | — | — | CN | disclosed |
| CN-101340912-A | (indazol-5-yl) -pyrazines and (1, 3-dihydro-indol-2-one) -pyrazines for the treatment of RHO kinase mediated diseases and conditions | ALCON MFG LTD (US) | 2009-01-07 | — | — | CN | disclosed |
| EP-1962853-A1 | (INDAZOL-5-YL)-PYRAZINES AND (1,3-DIHYDRO-INDOL-2-ONE)- PYRAZINES FOR TREATING RHO KINASE-MEDIATED DISEASES AND CONDITIONS | Alcon Research, Ltd. (US) | 2008-09-03 | — | — | EP | disclosed |
| EP-1962853-A1 | (INDAZOL-5-YL)-PYRAZINES AND (1,3-DIHYDRO-INDOL-2-ONE)- PYRAZINES FOR TREATING RHO KINASE-MEDIATED DISEASES AND CONDITIONS | Alcon Research, Ltd. (US) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007076360-A8 | (INDAZOL-5-YL)-PYRAZINES AND (1,3-DIHYDRO-INDOL-2-ONE)- PYRAZINES FOR TREATING RHO KINASE-MEDIATED DISEASES AND CONDITIONS | ALCON MFG LTD (US) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007076360-A1 | (INDAZOL-5-YL)-PYRAZINES AND (1,3-DIHYDRO-INDOL-2-ONE)- PYRAZINES FOR TREATING RHO KINASE-MEDIATED DISEASES AND CONDITIONS | ALCON RESEARCH, LTD. (US) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007076360-A1 | (INDAZOL-5-YL)-PYRAZINES AND (1,3-DIHYDRO-INDOL-2-ONE)- PYRAZINES FOR TREATING RHO KINASE-MEDIATED DISEASES AND CONDITIONS | ALCON RESEARCH, LTD. (US) | 2007-07-05 | — | — | WO | disclosed |
| US-20070149548-A1 | (INDAZOL-5-YL)-PYRAZINES AND (1,3-DIHYDRO-INDOL-2-ONE)-PYRAZINES FOR TREATING RHO KINASE-MEDIATED DISEASES AND CONDITIONS | ALCON MANUFACTURING, LTD. (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070149548-A1 | (INDAZOL-5-YL)-PYRAZINES AND (1,3-DIHYDRO-INDOL-2-ONE)-PYRAZINES FOR TREATING RHO KINASE-MEDIATED DISEASES AND CONDITIONS | ALCON MANUFACTURING, LTD. (US) | 2007-06-28 | — | — | US | disclosed |
| US-5532247-A | ACENAPHTHENES SUBSTITUTED IN THE 1-POSITION BY PYRIDYLMETHYL OR FLUOROPYRIDYLMETHYL; TREATING COGNITIVE OR NEUROLOGICAL DYSFUNCTION THEREWITH | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-07-02 | — | — | US | disclosed |
| US-5414004-A | Cognitive activators and nervous system disorders | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149548-A1 | (INDAZOL-5-YL)-PYRAZINES AND (1,3-DIHYDRO-INDOL-2-ONE)-PYRAZINES FOR TREATING RHO KINASE-MEDIATED DISEASES AND CONDITIONS | ROCK1, ROCK2, CIT | AHR 1111/4885PDK2 182/4885PDE3B 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.